announced on Zhejiang Ausun Pharmaceutical Co.Ltd(603229) 7 that the company signed the Shanghai Yikang phase II equity investment partnership (limited partnership) partnership agreement with all partners on March 7, 2022, and the company will subscribe 35 million yuan as a limited partner, accounting for 116667% of the total subscribed capital of 300 million yuan of Shanghai Yikang phase II equity investment partnership (limited partnership) (the “target fund”).
According to the announcement, no less than 90% of the actual contribution of the fund that can be used for investment will be used to invest in high-quality unlisted enterprises in the medical field at home and abroad in China. This move aims to explore the high-quality assets of the pharmaceutical industry in the future and tap excellent enterprises that master cutting-edge technologies in the fields of biotechnology, medical devices and innovative drugs.
